Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 23, 2026

AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push

View original at finance.yahoo.com

AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The company is committed to invest US$15 billion in China's biotech sector through 2030
60% confidence
AstraZeneca is the first multinational with end-to-end cell therapy manufacturing capability in China
60% confidence

Data points we hold from this source

AstraZeneca AB · return 1year	21.8 percent
AstraZeneca AB · return 1month	-9.0 percent
AstraZeneca AB · return 1week	-3.4 percent
AstraZeneca AB · return 3year	33.2 percent
AstraZeneca AB · return 5year	112.4 percent
AstraZeneca AB · return ytd	2.2 percent